{"created":"2024-04-24T05:32:53.028679+00:00","id":2001137,"links":{},"metadata":{"_buckets":{"deposit":"868f9ec4-b38f-4143-86d4-2a2967543354"},"_deposit":{"created_by":42,"id":"2001137","owners":[42],"pid":{"revision_id":0,"type":"depid","value":"2001137"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:02001137","sets":["14:923:1519:1713932063545"]},"author_link":[],"control_number":"2001137","item_30002_bibliographic_information29":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2024-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"25","bibliographicPageStart":"15","bibliographicVolumeNumber":"49","bibliographic_titles":[{"bibliographic_title":"ACTA MEDICA KINDAI UNIVERSITY","bibliographic_titleLang":"en"}]}]},"item_30002_creator2":{"attribute_name":"作成者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Hirase, Chikara","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Matsumura, Itaru","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Kumode, Takahiro","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Serizawa, Kentaro","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Morita, Yasuyoshi","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Tanaka, Hirokazu","creatorNameLang":"en"}]},{"creatorAffiliations":[{"affiliationNames":[{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"Fukuoka, Kazuya","creatorNameLang":"en"}]}]},"item_30002_description9":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Background: Nilotinib has been shown to be a more potent tyrosine kinase inhibitor of BCR::ABL1 than imatinib. We evaluated long-term efficacy and safety based on the 7-year follow-up data in patients with newly diagnosed chronic myeloid leukemia (CML) who were treated with nilotinib as the 1st-line therapy (1L-NIL) at the Kindai university hospital.\n\nMethods: In this single-center, observational study, we enrolled patients with newly diagnosed CML in chronic phase (CML-CP) who received 1L-NIL since December 2010, when nilotinib received regulatory approval for CML-CP in Japan. The primary endpoint was overall survival (OS) of the 1L-NIL patients. In addition, we analyzed molecular responses and safety profiles as the key secondary endpoints.\n\nResults: The median observation period was 6.8 (range: 1.2-12.3) years. The estimated OS and progression-free survival rates of the 1L-NIL patients (n=25) were both 95.5%. By 18 months, the cumulative achievement rates of major molecular response (MMR) and MR4.5 were 81.3% and 25.0%, respectively. Adverse events (AEs) occurred in 21 of 23 patients (91.3%) with Grade ≥3 in 8 of 23 patients (34.8%). We observed no unexpected serious AEs in this research.\n\nConclusions: Our data showed that the efficacy of nilotinib persisted over the 7-year follow-up and long-term administration of nilotinib was not associated with unacceptable late toxic effects at the Kindai university hospital.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_30002_file35":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"AA0050842X-20240600-0015.pdf","format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://kindai.repo.nii.ac.jp/record/2001137/files/AA0050842X-20240600-0015.pdf"},"version_id":"9b1b5e6d-2c66-4ec2-8aed-69e995aa6122"}]},"item_30002_identifier_registration17":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.15100/0002001137","subitem_identifier_reg_type":"JaLC"}]},"item_30002_language12":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_30002_publisher10":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"The Kindai University Medical Association","subitem_publisher_language":"en"}]},"item_30002_resource_type13":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_30002_source_identifier22":{"attribute_name":"収録物識別子","attribute_value_mlt":[{"subitem_source_identifier":"03866092","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"24327166","subitem_source_identifier_type":"EISSN"}]},"item_30002_subject8":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"chronic myeloid leukemia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"molecular targeted therapies","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"nilotinib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"outcome assessment","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_30002_title0":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital","subitem_title_language":"en"}]},"item_30002_version_type15":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_title":"Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital","item_type_id":"40004","owner":"42","path":["1713932063545"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-06-20"},"publish_date":"2024-06-20","publish_status":"0","recid":"2001137","relation_version_is_last":true,"title":["Long-Term Clinical Outcomes of the Patients with Chronic Myeloid Leukemia Treated with Nilotinib as the 1st-Line Tyrosine Kinases Inhibitor at the Kindai university hospital"],"weko_creator_id":"42","weko_shared_id":-1},"updated":"2024-06-24T06:15:43.253667+00:00"}